Details for Patent: 11,033,551
✉ Email this page to a colleague
Which drugs does patent 11,033,551 protect, and when does it expire?
Patent 11,033,551 protects MYFEMBREE and is included in one NDA.
This patent has sixty-two patent family members in twenty-four countries.
Summary for Patent: 11,033,551
| Title: | Methods of treating uterine fibroids |
| Abstract: | Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyr- idazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-- N'-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis. Further provided are methods of maintaining blood glucose profile, maintaining lipid profile, and/or maintaining bone mineral density in a pre-menopausal woman being treated for one or more conditions or symptoms of endometriosis, adenomyosis, uterine fibroids, or heavy menstrual bleeding; and methods of contraception and treating infertility. |
| Inventor(s): | Johnson; Brendan Mark (Chapel Hill, NC), Seely; Lynn (San Mateo, CA), Mudd, Jr.; Paul N. (Cary, NC), Wollowitz; Susan (Lafayette, CA), Hibberd; Mark (Hampshire, GB), Tanimoto; Masataka (Osaka, JP), Rajasekhar; Vijaykumar Reddy (Apple Valley, CA), Sukhatme; Mayukh Vasant (Mamaroneck, NY) |
| Assignee: | Myovant Sciences GmbH (Basel, CH) Takeda Pharmaceutical Company Limited (Osaka, JP) |
| Application Number: | 16/370,299 |
|
Patent Claim Types: see list of patent claims | Use; Dosage form; |
Drugs Protected by US Patent 11,033,551
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Myovant Sciences | MYFEMBREE | estradiol; norethindrone acetate; relugolix | TABLET;ORAL | 214846-001 | May 26, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE LEIOMYOMAS (FIBROIDS) IN PREMENOPAUSAL WOMEN | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,033,551
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 109759 | ⤷ Try a Trial | |||
| Argentina | 109762 | ⤷ Try a Trial | |||
| Argentina | 110636 | ⤷ Try a Trial | |||
| Australia | 2017334035 | ⤷ Try a Trial | |||
| Australia | 2017336338 | ⤷ Try a Trial | |||
| Australia | 2017336363 | ⤷ Try a Trial | |||
| Australia | 2022241582 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
